영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

auden mckenzie (pharma division) ltd - methadone hydrochloride - solution for injection - 25mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

auden mckenzie (pharma division) ltd - methadone hydrochloride - solution for injection - 10mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

auden mckenzie (pharma division) ltd - methadone hydrochloride - solution for injection - 10mg/1ml

남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

baxter healthcare south africa (pty) ltd - mesna a - injection - 400 mg - each 1 ml injection contains mesna a 100 mg

캐나다 - 영어 - Health Canada

sterinova inc. - naltrexone hydrochloride - tablet - 50mg - naltrexone hydrochloride 50mg - opiate antagonists

이스라엘 - 영어 - Ministry of Health

megapharm ltd - mesna - solution for injection - mesna 400 mg/vial - mesna - prevention of urinary passage toxicity of oxazaphosphorines (ifosfamide ,cyclophosphamide, trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, cyclophosphamide or trofosamide , urinary passage diseases in anamnesis.

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - mesna - solution for injection - 100mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - mesna - solution for injection - 100mg/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aop orphan ltd - naltrexone hydrochloride - oral tablet - 50mg

미국 - 영어 - NLM (National Library of Medicine)

a-s medication solutions - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm), bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - naltrexone hydrochloride 8 mg - contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (bmi) of: limitations of use: pregnancy category x risk summary contrave is contraindicated during pregnancy, because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard of maternal weight loss to the fetus. clinical considerations a minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. human data there are no adequate and well-controlled studies of contrave in pregnant women. in clinical studies, 21 (0.7%) of 3,024 women became pregnant while taking contrave: 11 carried to term and gave b